Impact of Noninvasive Targeted Pulsed Electromagnetic Field (tPEMF) on Opioid Use, Pain, and Joint Function Following Total Knee Arthroplasty

July 6, 2012 updated by: Amp Orthopedics, Inc.

Impact of Noninvasive Targeted Pulsed Electromagnetic Field (tPEMF) on Opioid Use, Pain, and Joint Function Following Total Knee Arthroplasty: A Double-Blind, Randomized, Sham-controlled Trial

The purpose of this study is to determine the effectiveness of pulsed radio frequency (PRF), a type of electromagnetic field treatment with the Ivivi Torino II for reducing post-operative narcotic use in patients recovering from Total Knee Arthroplasty.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

Surgeons are continually looking for means to minimize postoperative pain following TKA in order to reduce or eliminate the need for opioid pain medications. Reductions in pain and edema along with improvements in range of motion encourage quicker recovery of joint function and normal activities. Pulsed radio frequency (PRF), a type of electromagnetic field treatment is proven to effectively modulate postoperative pain and edema in plastic surgery. Therefore, PRF has potential as an adjunct therapy for patients recovering from TKA.

The purpose of the current double-blind, randomized, sham-controlled clinical trial is to determine the effectiveness and safety of the Ivivi Torino II, a device that delivers pulsed radio frequency (PRF), a type of electromagnetic field treatment, in patients recovering from TKA for treatment of severe knee OA.

Study Type

Interventional

Enrollment (Actual)

23

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Virginia
      • Alexandria, Virginia, United States, 22306
        • Anderson Orthopaedic Research Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 40 to 80 years
  • Primary diagnosis of knee OA
  • Appropriate candidate for TKA
  • Ability of the participant to comprehend the full nature and purpose of the study including possible risks and side effects
  • Consent to the study and willing to comply with study product and methods including follow-up

Exclusion Criteria:

  • Body mass index > 40 kg/m2
  • Scheduled for bilateral TKA
  • Advanced hip, spine, or ankle osteoarthritis that significantly limits ambulation
  • Subjects who have any implanted metallic leads, wires, or systems (e.g. pacemaker, implantable cardioverter-defibrillator)
  • Use of narcotic pain medication for any condition in the last 1 month prior to surgery
  • Self-reported diagnosis of post-traumatic or inflammatory arthritis (e.g. rheumatoid or psoriatic)
  • Pregnant or lactating female
  • Participation in any clinical trial in the past 30 days
  • Vulnerable populations including prisoners and nursing home residents
  • Any medical condition that, in the opinion of the investigator, may compromise patient safety or confound the assessment of treatment effectiveness

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Sham
Device: Ivivi Torino II
Targeted pulsed electromagnetic field treatment for 4 weeks post-surgery
Other Names:
  • Electromagnetic Field Therapy
Device: Ivivi Torino II
Sham treatment for 4 weeks post-surgery
Other Names:
  • Electromagnetic Field Therapy
Active Comparator: Targeted pulsed electromagnetic field
Device: Ivivi Torino II
Targeted pulsed electromagnetic field treatment for 4 weeks post-surgery
Other Names:
  • Electromagnetic Field Therapy
Device: Ivivi Torino II
Sham treatment for 4 weeks post-surgery
Other Names:
  • Electromagnetic Field Therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The average daily morphine equivalent dose consumption at 2 weeks post-surgery.
Time Frame: 2-week follow-up period from surgery
2-week follow-up period from surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Post-surgical opioid use during hospitalization and following discharge at 1 and 4 weeks post-surgery.
Time Frame: 1 and 4 weeks post-surgery
1 and 4 weeks post-surgery
Knee pain severity assessed on a 10 cm visual analogue scale (VAS)
Time Frame: At intervals over the 4-week follow-up period
Knee pain will be assessed for "current", pain at the time of data collection and "maximum", maximum pain experience at any point during the day of evaluation
At intervals over the 4-week follow-up period
The measurement of knee joint circumference
Time Frame: Measurement performed preoperatively, on the first or second postoperative day, at the discharge dressing change, and at the 4 week follow-up visit
With patient in supine position, the circumference of the extended knee will be measured 1 cm proximal to the base of the patella using the same type of tape measure in all patients
Measurement performed preoperatively, on the first or second postoperative day, at the discharge dressing change, and at the 4 week follow-up visit
Range of motion of the knee joint, assessed using the knee flexion technique
Time Frame: Assessed preoperatively, on the first or second postoperative day, at the discharge dressing change (unless discharged within 2 days), and at the 4 week follow-up visit
Range of motion will be assessed using the knee flexion technique, which allows the use of a goniometer with the trans-epicondylar axis of the knee joint as the fulcrum.
Assessed preoperatively, on the first or second postoperative day, at the discharge dressing change (unless discharged within 2 days), and at the 4 week follow-up visit
OA-related medication use including analgesics, anti-inflammatories, and other non-opioids
Time Frame: 4 weeks post-surgery
Subjects will be required to track daily OA-related medication use including analgesics, anti-inflammatories, and other non-opioids using a daily diary.
4 weeks post-surgery
Adverse Events collected and analyzed for confirmation of device safety
Time Frame: Randomization to 4 weeks post-surgery
Subjects will be instructed by the research staff and in the instructions in the daily diary to contact the research staff and/or investigator with any adverse events (AEs). Adverse events will be recorded daily.
Randomization to 4 weeks post-surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Amp Orthopedics, Inc.

Investigators

  • Principal Investigator: Gerard A. Engh, M.D., Anderson Orthopaedic Research Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2011

Primary Completion (Actual)

July 1, 2012

Study Completion (Actual)

July 1, 2012

Study Registration Dates

First Submitted

November 17, 2011

First Submitted That Met QC Criteria

November 17, 2011

First Posted (Estimate)

November 21, 2011

Study Record Updates

Last Update Posted (Estimate)

July 10, 2012

Last Update Submitted That Met QC Criteria

July 6, 2012

Last Verified

July 1, 2012

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IOH-TKA-001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Osteoarthritis, Knee

Clinical Trials on Ivivi Torino II

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe